Vall d'Hebron participates in an international position statement on the use of antihypertensive drugs in COVID-19 patients

Currently, in the absence of scientific evidence, a withdrawal of ACEis or ARBs is not recommended in hypertensive patients.

18/03/2020

Dr Maria José Soler, nephrologist at the Nephrology Service of the Vall d'Hebron University Hospital and member of the NephJC group. The Coronavirus Conundrum: ACE2 and Hypertention edition has participated in the position statement on the use of antihypertensive drugs such as ACEis or ARBs in patients infected with the SARS-CoV-2 virus and with hypertension prepared by the group. The document, which has been published in the kidney News Online journal of the American Society of Nephrology, recommends not stopping ACEIs or ARBs treatment in patients with confirmed COVID-19.

Angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor antagonists (ARBs) are common treatments for high blood pressure.

Several organizations (American College of Physicians, the European Society of Cardiology, Hypertension Canada, the Canadian Cardiovascular Society, UK Renal Association, and the International Society of Hypertension, among others) have released statements corroborating this approach.

The current pandemic associated with the SARS-CoV-2 virus and COVID-19 disease is unprecedented, and healthcare professionals face many challenges, including whether the combination of drugs for chronic diseases influences the severity of the patient with coronavirus.

In this sense, aware of this concern, doctors and researchers, among whom is Dr. Soler, who is also a principal investigator of the Nephrology group of the Vall d'Hebron Research Institute (VHIR), have prepared a consensus document on role of preliminary reports and articles that have appeared in different magazines on the role of angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor antagonists (ARBs) in the regulation of the expression of the gene of the angiotensin-converting enzyme 2 (ACE2). Several publications have pointed out that ACEis and ARBs agents could increase the regulation of ACE2 and, therefore, improve or facilitate the entry of SARS-CoV-2 into cells. Because the SARS-CoV-2 virus utilizes components of the renin angiotensin system (RAS) (ACE2 and TMPRSS2) to enter cells, it seemed plausible that ACEis and ARBs might exacerbate or even mitigate COVID-19.

Dr. Soler believes that "currently, in the absence of scientific evidence, a withdrawal of ACEis or ARBs is not recommended in hypertensive patients". "However, in patients with confirmed COVID-19 and who are receiving ACEi/ARB agents, decisions on continuing or stopping these drugs should be done on an individualized basis by the treating physician", he points out.

This document will be updated based on new preclinical and clinical evidence, highly necessary at present.

Share it:

Related news

Subscribe to our newsletters and be a part of Vall d'Hebron Campus

The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”.
Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health).
Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information.
Legal basis: Consent of the data subject.
Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen.
Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time.
Source: The data subject.
Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.